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INTRODUCTION 
 
Mortality and morbidity due to either a cardiovascular or a cerebro-vascular 
event is not always just an occurrence by chance, but a predetermined insult 
that might have built up over several years if not decades. Such a build up of a 
disease is perpetuated by several components, as described by risk factors, some 
conventional, some non-conventional; some modifiable, some not. 
The metabolic syndrome is a conglomeration of some of such risk factors and 
which when present over a period of time predispose to disease processes in 
various body systems. The risk factors as the name suggests have a genetic and 
metabolic background and thus the disease is not uniform in various ethnic 
groups. However, the presence of these factors under the term `The Metabolic 
Syndrome` places the patient under a significant cardiovascular and cerebro-
vascular disease risk among other processes. This study is aimed to evaluate   
the metabolic syndrome in its various aspects and the events associated with it 
namely the carotid intima media thickness, left ventricular diastolic dysfunction 
and proteinuria.        
AIMS OF THE STUDY 
1. To evaluate the factors defining the metabolic syndrome in patients attending                                                                                                   
the medical out-patient department for non-specific symptoms and who were 
found to have impaired glucose tolerance or a high blood pressure or are obese. 
2. To evaluate such patients identified to have the metabolic syndrome for 
Carotid Intima-media thickness Left ventricular diastolic dysfunction and 
Proteinuria.  
3. To evaluate the above mentioned factors in metabolic syndrome. 
4. To study about the co-morbid factors in metabolic syndrome and their 
influence in the outcome of events studied. 
 
 
REVIEW OF LITERATURE 
 
Metabolic syndrome is the term used to describe a constellation of metabolic 
derangements that include insulin resistance, hypertension, dyslipidemia, 
central or visceral obesity, type 2 diabetes mellitus or IGT/IFG, and accelerated 
cardiovascular disease. 
Metabolic syndrome is very common. 
The centers for disease control and prevention estimates that 20% of the US 
adults have metabolic syndrome. Indian studies report a prevalence that varies 
between 12.8% and 25.8% 12. 
 
THE SYNDROME X, THE INSULIN RESISTANCE SYNDROME  & 
THE METABOLIC SYNDROME: 
Sensitivity to insulin-mediated glucose disposal varies widely in the population 
at large3. When insulin resistant individuals cannot maintain the degree of 
hyperinsulinemia needed to overcome the insulin resistance, type 2 diabetes 
develops 4,5. Most individuals are able to sustain the level of compensatory 
hyperinsulinemia needed to maintain a normal or near normal glucose 
tolerance, however. Unfortunately, this philanthropic effort on the part of the 
pancreatic beta cell is a mixed blessing. Although the compensatory 
hyperinsulinemia prevents the development of frank hyperglycemia, insulin-
resistant/hyperinsulinemic individuals are greatly at risk of having some degree 
of glucose intolerance, a high plasma triglyceride and low high-density 
lipoprotein (HDL-C) concentration and hypertension.6. Earlier, in 1988, it was 
proposed that individuals who displayed this cluster of abnormalities associated 
with insulin-resistance, compensatory hyperinsulinemia were at significantly 
high risk of cardiovascular disease (CVD). Because the importance of insulin 
resistance and associated abnormalities as CVD risk factors was not widely 
appreciated at that time, the cluster of related abnormalities was assumed under 
the rubric of SYNDROME X.     
Since the introduction of the concept of Syndrome X, a relatively enormous 
amount of new information has evolved relevant to the role of insulin resistance 
in human diseases. This resulted in two somewhat disparate approaches to 
thinking about the clinical implications of insulin resistance and its 
consequences.  
One view represents an effort to acknowledge that the abnormalities related to 
insulin resistance have broadened considerably and the adverse clinical 
outcomes extend beyond type 2 diabetes and CVD. Because CVD is recognized 
as just one of the multiple clinical syndromes associated with insulin resistance, 
It seems appropriate to replace the term with one more aptly deals with this new 
information. In this context, the insulin resistance syndrome (IRS) seems to 
be a logical choice to provide a pathophysiologic construct with which to view 
the different clinical syndromes that occur more commonly in insulin resistant 
individuals. On a somewhat parallel tract, during this period when the list of 
abnormalities associated with insulin resistance was rapidly expanding, the 
cardiology community has formally acknowledged the importance of this defect 
in insulin action as CVD risk with th-e report of the Adult treatment panel III of 
the national cholesterol education program 6. The ATP III recognized the 
importance of CVD risk factors of what they referred to as a “constellation of 
lipid and non-lipid risk factors of metabolic origin,” designated this cluster as 
the METABOLIC SYNDROME, and stated this syndrome is closely related 
to insulin resistance. The goal of the metabolic syndrome is to provide the tools 
believed necessary to identify presumably insulin resistant individuals at 
increased risk of cardiovascular disease (CVD). In marked contrast to the 
notion of the IRS, its focus is not to provide a physiologic construct with which 
to put into a cause and affect perspective all of the clinical syndromes that are 
more likely to occur in insulin resistant individuals. Instead, it should be 
considered a diagnostic tool and its value evaluated in light of the clinical use of 
making a diagnosis of the metabolic syndrome by satisfying three of the five 
criteria listed below. The variables listed in the box seem to have been selected 
because they seem to cluster together and occur more commonly in insulin 
resistant individuals.  
 
DEFINITIONS: 
Definitions of the metabolic syndrome that also include a measure of central 
obesity have been developed between 1999 and 2001 by the World health 
organization (WHO consultation 1999), the European group for the study of 
insulin resistance (EGIR; Balkau and Charles, 1999) and the national 
cholesterol education program (NCEP) expert panel on detection, evaluation 
and treatment of high blood cholesterol in adults (abbreviated to Adult 
treatment panel, ATP-III). 
The ATP-III criteria also recognized the association between the above factors 
of the metabolic syndrome and pro-inflammatory and pro-thrombotic states as 
reflected by increased C-reactive protein and plasma plasminogen activator 
inhibitor levels, respectively, but these are not required for the definition of the 
syndrome. 
 
 
 
 The five criteria selected by the ATP III to identify individuals with metabolic 
syndrome are given below, 
 
 
ATP III criteria for diagnosing the metabolic 
syndrome. 
 
 1.Abdominal obesity  
                 Men: waist circumference > 40 inches 
                 Women: waist circumference >35 inches                                                                               
 2. Fasting glucose > 110  
 3. Blood pressure > 130/85 mm Hg. 
 4. Triglycerides   > 150 mg/dl 
 5. HDL-C      Men: < 40 mg/dl 
                       Women: < 50 mg/dl 
The metabolic syndrome is present when three or more 
of the five criteria are met. 
 
 
 
The other criteria include the WHO criteria and the European group for the 
study of insulin resistance. According to the WHO criteria, demonstration of 
glucose intolerance and microalbuminuria are required for the diagnosis of the 
metabolic syndrome.    
 
     
The WHO and EGIR criteria are described in the table given below, 
 
 
 WHO Criteria       EGIR Criteria 
 
 
Central obesity  
 
WHR>0.9-men            
          > 0.85-women  
            BMI>30kg/sq. M 
  
 
Waist > 94cm-men 
            > 80cm-women 
Blood pressure (mmHg)  >140/90                          >140/90 or treated 
(mmHg) for HT 
 
Dyslipidemia   TGL> 150mg/dl  
 HDL< 0.9 male                  
         <1.0-female  
 
TGL >175                                 
HDL < 1.0 or                                             
                                                                          
Dysglycemia FPG> 110 and or                                   
2 h post-challenge         
non-diabetic.                                    
Glucose>140 on                                    
diabetics 
 
FPG >110 but non-
diabetic 
Insulin resistance  Glucose uptake                                                  
during hyperinsulinemic                                   
euglycemic clamp in 
lowest quartile  
for population 
 
 
                 - 
Other factors  Microalbuminuria 
 
                  - 
 
Because of the effectiveness and the practicality of the ATP III criteria, it is 
taken as the reference criteria in this study.    
It is well reported in various studies that the upper limit of the Waist 
circumference has to be tailor- made for each ethnic group. 53  
Hence, in our study, the Modified ATP III criteria, with Waist circumference 
of more than or equal to 90cm in male, and 85 cm for female has been taken  2, 
53, 73,74.
  
 
Pathogenesis of the metabolic syndrome: 
 Resistance to the action of insulin is a central feature of the metabolic 
syndrome. Liver, skeletal muscle and adipose tissue are considered the major 
insulin-responsive tissues but the vasculature also can be considered as an 
insulin-responsive organ. In the metabolic syndrome insulin resistance is linked 
predominantly to a cluster of disorders involving triglyceride and glucose 
metabolism, increased blood pressure and vascular inflammation. Although to 
date there is no central unifying mechanism that explains all of the features of 
the syndrome, it is most likely that certain of the features occur as secondary 
consequences of a primary abnormality (or several primary abnormalities). 
Given that insulin resistance is fundamental to a diagnosis of the syndrome, an 
understanding of the cause and consequences of insulin resistance is crucial to 
an understanding of the pathogenesis of the metabolic syndrome. 
Low levels of physical activity and relatively high dietary calorie intake 
adversely affect the metabolic profile by decreasing free fatty acid (FFA) and 
glucose oxidation in skeletal and cardiac muscle, which potentially contribute to 
body fat accumulation and resistance to the biological actions of insulin. 
Because many cytokines, such as tumor necrosis factor (TNF)-alpha, 
interleukin (lL-6 and IL-1), are secreted by adipose tissue, increasing levels of 
obesity are often associated with increased concentrations of these 
proinflammatory cytokines. Chronic low-grade inflammation is undoubtedly a 
component of the metabolic syndrome but the mechanisms linking insulin 
resistance and inflammation are uncertain (Nesto, 2004). Proinflammatory 
cytokines such as TNF-alpha may mediate a link between inflammation and 
some of the metabolic abnormalities occurring with the metabolic syndrome. 
For example, TNF-alpha decreases insulin-induced suppression of hepatic 
glucose production, increases fatty acid and cholesterol synthesis, increases 
hepatic very-low-density lipoprotein (VLDL) production and increases 
adipocyte lipolysis. Increased lipolysis causes increased concentrations of non-
esterified fatty acids (NEF As), which also provide a stimulus and a substrate 
for hepatic triglyceride synthesis, to increase further VLDL assembly and 
secretion. Thus if there is increased lipolysis, such as also occurs in patients 
with obesity or lipodystrophy, an increased supply of NEFAs to the liver has 
adverse consequences for lipoprotein metabolism. Increased plasma NEFA 
concentrations also potentially may interfere with glucose metabolism by 
reducing glucose uptake and oxidation. Consequently, increased NEFA 
concentrations and increased TNF-alpha probably contribute to the classical 
dyslipidaemia associated with the metabolic syndrome and diabetes, namely 
increased fasting plasma triglyceride concentrations, decreased HDL-
cholesterol and increased LDL-cholesterol concentrations, as well as potentially 
contributing to increased plasma glucose. 
Within the vasculature the metabolic syndrome is also associated with an 
increase in cellular reactivity. For example, there is evidence of endothelial cell, 
platelet and monocyte activation, such that these cell types are often in a 
reactive state. Activation of these key cells predisposes an individual to a pro-
coagulant and pro-inflammatory vascular phenotype that probably precedes 
development of atheromatous plaques. Not only does a developing plaque 
induce changes within other cell types in the vasculature but dysfunctional 
activated cell types, such as endothelial, monocyte and platelets, will induce 
changes in the metabolism of other tissues. Thus it is difficult to distinguish 
precise causes from subsequent consequences, not least because the metabolic 
syndrome comprises a dynamic process of evolving vascular and metabolic 
disease. Cross-sectional studies of plaque biology only study molecular changes 
within the plaque and the surrounding vasculature at a given instant in time. 
Understanding the molecular pathogenesis of plaque evolution and healing 
requires monitoring of the whole process, which is not currently possible. 
The immune response is undoubtedly involved in the developing atheromatous 
plaque, but whether a primary disorder of the immune response causes the 
predisposition to vascular inflammation in the metabolic syndrome is not clear. 
Within the plaque, helper T cells are predominantly THI cells, secreting 
generally pro-inflammatory cytokines. However, with marked hyperlipidaemia, 
in some animal models of atheroma and in atherosclerotic aneurysmal disease a 
shift to TH2 cells, or those secreting predominantly anti-inflammatory 
cytokines, has been noted. Whether this finding represents part of the causal 
pathway, is a consequence of the inflammatory disease process or represents a 
physiological healing response is uncertain. 
Adiponectin is a recently described molecule that may be important in the 
pathogenesis of the metabolic syndrome. Adiponectin is exclusively secreted by 
adipocytes (Fain et al, 2004) and has high affinity for adiponectin receptors 
expressed in two other insulin-sensitive tissues, namely skeletal muscle and the 
liver (Yamauchi et al, 2003). It has been shown that adiponectin concentrations 
are decreased in insulin resistance with either obesity or lipodystrophy. 
Interestingly, and relevant to the pathogenesis of the metabolic syndrome, 
treatment with adiponectin increases insulin action and ameliorates features of 
the metabolic syndrome (Chandran et al, 2003; Diez and Iglesias, 2003; Kinlaw 
and Marsh, 2004). In transgenic mice in which the adiponectin gene was 
'knocked out', adiponectin deficiency caused diet-induced glucose intolerance, 
insulin resistance and increased NEFA concentrations (Kubota et al, 2002; 
Maeda et al, 2002). Increased expression of the adiponectin gene also has been 
shown to increase insulin sensitivity, improve glucose tolerance and decrease 
NEFA concentrations (Combs et al, 2004). Thus, these results suggest a 
beneficial effect of increased adiponectin concentrations to decrease insulin 
resistance and ameliorate features of the metabolic syndrome. Adiponectin may 
not only have a direct beneficial effect on insulin sensitivity, fat and glucose 
metabolism but may also confer benefit within the vasculature, mediated 
through its ability to increase the phosphorylation and activation of 
AMPK/malonyl-CoA signaling, and to decrease the inflammatory pathway via 
reduction of nuclear factor (NF)-KB activity (Chandran et al, 2003; Diez and 
Iglesias, 2003; Goldstein and Scalia, 2004). Specifically in endothelial cells 
adiponectin signaling acts to suppress inflammatory changes by blocking 
inhibitory NF-KB phosphorylation and NF-KB activation. The NF-KB/Rel 
family of proteins are inducible transcription factors that play a central role in 
regulating the expression of a wide variety of genes associated with cell 
proliferation, inflammation and cell survival (Ghosh and Karin, 2002; Li and 
Verma, 2002). Thus, the net effect of increased adiponectin signalling is 
increased fatty acid oxidation, increased glucose utilization, reduced 
endogenous glucose production and decreased inflammation (Chandran et al., 
2003; Diez and Iglesias, 2003). 
Insulin resistance also may lead directly to impaired endothelial function. 
Endothelial cells respond to insulin, and insulin resistance is associated with 
impaired endothelium-dependent vasodilatation in response to acetylcholine. 
Furthermore, it has been shown that hyperinsulinaemia can increase the 
expression of the adhesion molecule ICAM-l, increasing macrophage 
attachment to the endothelium (Nesto, 2004). Healthy endothelium should not 
normally facilitate binding of leucocytes. Activated endothelial cells express 
adhesion molecules that bind various classes of leucocytes. In particular, 
vascular cell adhesion molecule-l (VCAM-1) binds those classes of leucocytes 
found in atheromatous plaques, namely the monocyte and the T lymphocyte. 
The mechanism of VCAM-l induction probably depends on inflammation 
instigated by modified lipoprotein particles accumulating in the arterial intima 
in response to the hyperlipidaemia that may be relevant to the metabolic 
syndrome. Constituents of modified lipoprotein particles, among them certain 
oxidized phospholipids and short-chain aldehydes arising from lipoprotein 
oxidation, can induce transcriptional activation of the VCAM-J gene mediated 
in part .by NF-KB (Collins and Cybulsky, 2001), and pro-inflammatory 
cytokines such as IL-l or TNF-a which are increased with the metabolic 
syndrome, induce VCAM-l expression by this pathway. Thus, pro-
inflammatory cytokines may link altered endothelial function to the 
dyslipidaemia of the metabolic syndrome. 
There are many similarities between Cushing's disease (or syndrome) and the 
metabolic syndrome. These similarities have suggested to investigators that 
some component of the cortisol production or signalling pathway may be 
involved in the pathogenesis of the metabolic syndrome. However, the 
mechanism by which glucocorticoid hormone action contributes to the 
metabolic syndrome has not been fully elucidated, Many of the properties of 
glucocorticoid hormones are antagonistic to the actions of insulin, with 
important consequences for carbohydrate and lipid metabolism, suggesting a 
key role for abnormal glucocorticoid action in the metabolic syndrome. A 
recent review on this topic discusses the actions of glucocorticoids in the 
metabolic syndrome in more detail (Wang, 2005). Glucocorticoid hormones 
also have a permissive effect to enhance actions of other insulin counter-
regulatory hormones such as adrenaline and glucagon. For example, 
glucocorticoid hormones enhance the sensitivity of adipocytes to adrenaline to 
increase lipolysis and to skeletal muscle to release lactate. Glucocorticoid 
hormones acutely activate lipolysis in adipose tissue. Lipolytic activity and 
consequently plasma FFA levels are reduced in adrenalectomized animals and 
return to normal within 2 h after glucocorticoid administration. This permissive 
effect may be mediated by altered sensitivity to other lipolytic hormones, such 
as catecholamines and growth hormone, but the molecular mechanisms 
responsible are uncertain. Several authors have suggested that a neuroendocrine 
disturbance involving the hypothalamic-pituitary axis (HPA) may play an 
important part in the causation of the metabolic syndrome (Pasquali er al, 1993; 
Bjorntorp, 1995). Case-control and cross-sectional studies show that elevated 
plasma cortisol concentrations in morning samples are associated with high 
blood pressure, glucose intolerance, insulin resistance and hyperlipidaemia 
(Filipovsky et al, 1996; Stolk et al, 1996; Phillips et al., 1998). In contrast, other 
studies, particularly of centrally obese subjects, show a flattening of 24-hr 
cortisol secretion with reduced morning cortisol concentrations (Marin et at., 
1992; Hautanen and Adlercreutz, 1993; Pasquali et al, 1993; Rosmond, 
Dallman and Bjorntorp, 1998). Thus it is unlikely that altered activity of the  
HPA alone underlies the etiology of the metabolic syndrome. 
Recent evidence has suggested that altered cellular glucocorticoid hormone 
action may mediate features of the metabolic syndrome. Genetic 
polymorphisms of the glucocorticoid receptor (GR) have been described that 
alter glucocorticoid hormone action and are associated with features of the 
metabolic syndrome (Weaver, Hitman and Kopelman, 1992). However, recent 
studies suggest that the relative contribution of GR genotype to blood pressure 
is small (Kenyon et al., 1998). This has led to suggestions that tissue-specific 
molecular determinants of glucocorticoid hormone action may underlie the 
causative role of modest alterations in glucocorticoid hormone action in the 
pathogenesis of the metabolic syndrome (Buemann et al, 1997; Panarelli et al, 
1998). Altered patterns of GR expression in skeletal muscle are associated with 
the metabolic syndrome. In a cross-sectional study to investigate relationships 
between glucocorticoid hormone action and insulin sensitivity 
hyperinsulinaemic euglycaemic clamps and skeletal muscle biopsies were taken   
in 14 men (Whorwood et al., 2002). In muscle cell cultures established from 
these subjects it was showed that GR mRNA levels are positively correlated 
with the degree of insulin resistance. These data suggest a strong link between 
tissue sensitivity to glucocorticoid hormone and both resistance to insulin-
mediated glucose uptake in skeletal muscle and obesity. The net effect of 
increased tissue glucocorticoid activity may contribute to the pathogenesis of 
the metabolic syndrome but more evidence is needed. In physiological states, 
plasma glucocorticoid hormones circulate as plasma protein-hormone 
complexes with a corticosteroid-binding globulin. Free hormone diffuses into 
the cell and binds intracellular GR. After binding of hormone to cytosolic GR, 
there follows translocation of the complex to the nucleus. Ligand-bound GR 
interacts with a number of transcript factors, including API, and through 
interactions between these GR-transcription factor complexes and complex 
glucocorticoid response elements it brings about regulation of gene expression. 
Whether any component of this process affects or is altered by the metabolic 
syndrome is uncertain. 
By comparison there has been considerable recent interest in the role of II 
f3hydroxysteroid dehydrogenase (11f3-HSD) in the pathogenesis of the 
metabolic syndrome, as discussed in a recent review by Seckl and Walker 
(2004). Dynamic regulation of intracellular cortisol levels is mediated 
predominantly by the activity of the II f3-HSD enzymes, which can be regarded 
as pre-receptor signalling mechanisms regulating glucocorticoid hormone 
action through the conversion of hormonally active cortisol to inactive 
cortisone, or vice versa. Clinical and experimental animal studies have revealed 
the expression of at least two kinetically distinct 11f3-HSD isoforms, which 
have been characterized (White, Mune and Agarwal, 1997; NarayFejes-Toth, 
Colombowala and Fejes-Toth, 1998). Type I llf3-HSD (1lf3-HSD-l) encodes 
relatively low-affinity NADP/NADPH-dependent II-dehydrogenase (cortisol to 
cortisone) and oxo-reductase (cortisone to cortisol) activity (Km for cortisol = 1 
J,JM, Km for cortisone = 0.3 ~M). In contrast, type 2 1113-HSO (1113HSO-2) 
encodes high-affinity NAO-dependent ll-dehydrogenase activity. The kinetic 
characteristics of these isoforms, together with their distinct tissue-specific 
distribution, suggest distinct physiological roles (Whorwood, Ricketts, and 
Stewart 1994; Whorwood et al., 1995). 
Recent evidence has also suggested a role for cortisol metabolism in the 
possible pathogenesis of programming of the metabolic syndrome. Fetal 
overexposure to increased concentrations of glucocorticoids may influence 
subsequent development of the metabolic syndrome in adulthood. 
Glucocorticoids slow fetal growth and may alter the size of the placenta, 
depending on the dose and timing of exposure (Langley-Evans. 1997). These 
prenatal effects appear to persist after birth, e.g. if a moderate dose of 
dexamethasone (a synthetic glucocorticoid that readily passes through the 
placenta) is given to a pregnant rat it results in fetal growth retardation (average 
reduction by approximately 14 per cent), without affecting the gestation time or 
the viability of the fetus. A rise in systolic blood pressure in the adult offspring 
has been observed months after this exogenous glucocorticoid exposure 
(Benediktsson et al., 1993). Glucocorticoids have important effects on the 
maturation of tissues involved in blood pressure control. For example, 
development of catecholamine receptor expression is affected, and 
glucocorticoids influence second messenger systems in renal and vascular 
tissue. Glucocorticoids also may affect blood pressure by inducing growth 
factors such as IGF or, alternatively, via indirect effects on carbohydrate and fat 
homeostasis (Seckl, 1994). In sheep, fetal blood pressure is increased when 
glucocorticoids are infused into the mother. The glucocorticoids affect the 
blood pressure directly by potentiating vasoconstrictor effects on the 
vasculature and also by regulating the synthesis of catecholarnines, nitric oxide 
and angiotensinogen, as well as having actions on the central nervous system 
(Tangalakis et al, 1992). Fetal cortisol levels are raised' in intra-uterine growth 
retardation (Goland et al., 1993) and normally the fetus is protected from high 
maternal levels of physiological glucocorticoids (5-10 times higher 
concentration than in the fetus) by the placental enzyme 111beta-HSO-2, which 
catalyses conversion of active cortisol to inactive cortisone. The efficiency of 
the placental barrier to maternal glucocorticoids varies considerably (Edwards 
et al., 1993) and prenatal glucocorticoid exposure affects maturation of organs, 
an effect that may persist throughout life (Goland et al., 1993). In rats, the 
lowest placental 111beta-HSO-2 activity, and therefore presumably the highest 
fetal exposure to maternal glucocorticoids, is associated with low-birth weight 
fetuses, presumably as a result of cortisol retarding growth. It is these fetuses 
that develop the highest blood pressure, blood glucose and glucocorticoid levels 
in adulthood (Benediktsson et al., 1993). Treatment of pregnant rats with an 
111beta-HSO-2 inhibitor, carbenoxolone, also reduces birth weight (by up to 20 
per cent) and raises blood pressure in the adult offspring (mean increase of 7-9 
mmHg) (Walker et al, 1998). However the effect of fetal exposure to increased 
cortisol levels may differ depending upon the timing of exposure during 
gestation because the intracellular GR is expressed in most fetal tissues from 
mid-gestation.  
 
CLINICAL CONSEQUENCES OF THE METABOLIC SYNDROME:  
The association of the Metabolic Syndrome with Cardiovascular events is well 
known and is the dogma of this study. In addition to the increased risk of 
cardiovascular disease, patients with the metabolic syndrome are also 
predisposed to the following clinical syndromes- type 2 diabetes, peripheral 
arterial disease, gall stones, asthma, essential hypertension, PCOD,  
non- alcoholic fatty liver disease, certain forms of cancer and sleep apnea. 53. 
The relative risk of Diabetes Mellitus is at least threefold higher among people 
with the metabolic syndrome than among those without the syndrome. Relative 
risks of the metabolic syndrome are highest for coronary artery disease 
mortality in various studies. Based on the data from the Framingham Offspring 
Study of 3323 men and women (mean age 52) with an 8 year follow-up it has 
been estimated that the metabolic syndrome (as defined by the ATP III criteria) 
contributed almost half of the population-attributable risk for Diabetes and 
approximately a quarter of all incident cardiovascular disease. 71, 72   
 
Evaluation of the Adult treatment panel III diagnostic criteria 53: 
 
WAIST CIRCUMFRENCE:  the inclusion of a measure of excess adiposity as 
one of the ATPIII criteria for identifying individuals with the metabolic 
syndrome is interesting because, as distinguished from other criteria, it is not a 
consequence of insulin resistance. Instead, obesity seems to be a life style 
variable that, along with physical inactivity, has an adverse effect on insulin 
mediated glucose disposal 7,8,9 which increases chances that the abnormalities 
and clinical syndromes associated with insulin resistance/compensatory 
hyperinsulinemia will develop. Although waist circumference may be more 
closely related to insulin resistance and its consequences than generalized 
obesity as estimated by body mass index, its superiority as a clinical tool can be 
questioned. The evidence that the waist circumference is more sensitive than 
body mass index as an approach to identify insulin resistant individuals at 
increased risk of developing CVD comes from the results presented by the 
European group for the study of insulin resistance10. These investigators 
evaluated the relationship between insulin mediated glucose disposal as 
measured by the euglycemic clamp technique and obesity in more than 1100 
volunteers without diabetes. They reported that the magnitude of correlation 
between insulin resistance and obesity did not increase when the ratio of waist 
to hip was substituted for body mass index as the marker for obesity.  
The following paragraph contains the directions for measuring waist 
circumference according to the national health and nutritional survey protocol11 
 `The subject stands and the examiner at the right palpates the upper bone 
to locate the iliac crest. Just above the uppermost lateral border of the right iliac 
crest, a horizontal is drawn, and then crossed with a vertical mark on the mid-
axillary line. The measuring tape is placed in a horizontal plane in the abdomen 
at the level of the marked point. The plane of the tape is parallel to the floor and 
the tape is snug, but does not compress the skin. The measurement is made at 
normal minimal inspiration’. 
To use waist circumference as one of the criteria, the upper limit of normal 
would have to be almost tailor-made for each ethnic group 53.  In this study WC 
more than or equal to 90 for males and 85 for females was used instead of 102 
and 88 respectively as per the ATPIII criteria 2, 53, 73, 74. These were derived using 
the mean +1 SD of the value for the non-diabetic, non-obese healthy people in 
tamilnadu (chennai) 12. 
 
 
FASTING PLASMA GLUCOSE CONCENTRATION: 
The American diabetic association has proposed the term `impaired fasting 
glucose` be used to describe individuals with a fasting plasma glucose 
concentration of 110 to 126 mg/dl (13) and that they may be prediabetic. 
Because a value of more than 126 is indicates diabetes and unequivocally 
increases the risk of CVD, it seems likely that the selection of ATPIII is to 
detect people with insulin resistance from the new ADA diagnostic criteria.  
The results of the DECODE study group14, 15 showed that post glucose 
challenge plasma concentration were superior to fasting values in predicting the 
CVD risk.of the 490 people, 25% of the individuals in the normal glycemic 
range were insulin resistant. These findings indicate that the presence of 
impaired fasting glucose occurs too frequently to be useful in the diagnosis of 
the metabolic syndrome. 
 
 
BLOOD PRESSURE: 
The relationship between insulin resistance, blood pressure and risk of CVD is 
significant because though no more than 50% of patients with essential 
hypertension are insulin resistant that this is the subset of patients at risk of 
CVD. 
Those patients with ECG evidence of ischemia and hypertensive are more 
glucose intolerant and hyperinsulinemic than those who are not. Dyslipidemia 
was observed in a significantly increased number in these patients than in 
normotensives. 
The Copenhagen Male Study 16 and Jeppenson et al 17 showed the 
development of CVD in individuals with a high triglyceride and low HDL-C 
concentration was independent of the differences in baseline systolic or 
diastolic blood pressure. In contrast, the higher the systolic or diastolic blood 
pressure was at the beginning of the study, the greater the incidence of CVD in 
individuals without the dyslipidemic changes associated with insulin resistance. 
 
DYSLIPIDEMIA: 
The dyslipidemic components of the metabolic syndrome are probably the 
features linked most closely with insulin resistance and the risk of CVD. The 
ability of a low HDL-C to predict risk of CVD is well known for years. The role 
of increased triglycerides as an independent risk factor is well documented in 
recent studies 18,19. Evidence from the Helsinki Heart Study and the Veterans 
Affairs HDL Intervention Trial (VA-HIT) study 20 demonstrates that the use 
of Gemfibrozil, an agent that lowers plasma triglycerides and raises HDL-C 
concentrations, significantly decreases risk of CVD 2021. VA-HIT also postulates 
that those who had the highest plasma insulin concentrations at baseline and 
were presumably the most insulin resistant benefited the most from gemfibrozil 
treatment. 
 
An overview of PROTEINURIA:  
 
Microalbumiuria has emerged in the last decade as a recognized independent 
cardiovascular risk factor in addition to being a predictor of diabetic kidney 
disease 22,23.  It has been associated with essential hypertension 24,25; elevate 
triglycerides, total cholesterol and reduced HDL cholesterol, endothelial 
dysfunction 26,27,28, all features of the metabolic syndrome 29,30. 
The significance of microalbuminuria was first described in 1982 by Viberti et 
al., who showed a 24 fold increased risk of development of clinical proteinuria 
in Type 1 diabetic patients 31. The finding was later extended to be associated 
with Type 2 diabetes mellitus also 32 33 34. Similar observations in non-diabetic 
individuals have also been reported in population studies 35-40. Thus proteinuria 
is an independent cardiovascular risk factor, the pathophysiology of which may 
be related to insulin resistance or hyperinsulinemia. It is probable that insulin 
resistance and proteinuria are both manifestations of a central mechanism yet to 
be identified which causes the clustering of metabolic and hemodynamic 
derangements in cardiovascular disease. In essential hypertension or diabetes, 
insulin resistance can be found in the absence of proteinuria but the reverse is 
uncommon. Therefore, the presence of proteinuria in these patients should serve 
as a warning signal for the metabolic syndrome.       
 
 CAROTID INTIMA MEDIA THICKNESS: 
Carotid sonographic imaging is valuable in the determination of the presence 
and extent of disease. Visual inspection of longitudinal gray-scale images of the 
layers of normal carotid wall demonstrates two nearly parallel echogenic lines, 
separated by a hypoechoic to anechoic region. The first echo, bordering the 
vessel lumen, represents the lumen-intima interface; the second echo is caused 
by the media adventitia interface. The media is the anechoic/hypoechoic zone 
between the echogenic lines. The distance between these lines represents the 
combined thickness of the intima and media (I-M complex). The free wall of 
the Common carotid artery is measured. Normal thickening is usually less than 
0.8mm. An increase in carotid IMT may represent the earliest changes of 
atherosclerotic disease. IMT increases with age. Numerous articles support the 
relationship between IMT and increased risk of myocardial infarction and 
stroke in asymptomatic populations 41,42,43.  A recent reference suggests that IMT 
may be superior to the coronary artery calcification score for identifying 
patients at high risk for these cardiovascular events 44. Assessment of carotid 
IMT has been advocated as a means of assessing effectiveness of medical 
interventions to reduce the progression of IMT or even reverse carotid wall 
thickening.  
 
LEFT VENTRICULAR DIASTOLIC DYSFUNCTION: 
Left ventricular diastolic dysfunction is recognized as an important contributing 
factor in the pathophysiology of many common cardiovascular diseases. 
Diastolic dysfunction may be present prior to, or concomitant with, systolic 
dysfunction. Although treatments are often aimed at improving the left 
ventricular contractile performance, they may conflict with appropriate therapy 
for diastolic abnormalities. Recently, attention has been increasingly directed 
towards the diagnosis, evaluation, and treatment of diastolic dysfunction. 
 
LVDD in METABOLIC SYNDROME:  
Abnormalities of left ventricular filling have been reported in asymptomatic, 
otherwise healthy obese persons who have some degree of insulin resistance 
45,46
. Prolongation of isovolumetric relaxation time is a common finding in obese 
individuals. These findings may be noted in the absence of systolic dysfunction 
and are consistent with diastolic dysfunction. It is possible that impaired 
relaxation, compliance or both occur in the metabolic syndrome. Weight 
reduction and control of other factors is associated with improvement in left 
ventricular diastolic filling and isovolumetric relaxation 47,48.  
 
Echocardiography findings include, decreased peak early filling velocity, 
increased peak atrial filling velocity, reduced peak early to atrial filling velocity 
ratio, increased atrial contribution to filling and reduced deceleration rate of 
early filling 49. 
 
The use of pulsed Doppler echocardiography to describe events of left 
ventricular filling is based on the assumption that transmitral blood flow 
velocities are representative of volumetric flow. The typical pulsed wave 
Doppler transmitral spectral pattern is shown below in figure A. 
 
The two phases of forward flow in early diastole and late diastole can be readily 
identified by their triangular shape and are separated by a brief period of 
diastasis. The early phase, or E wave represents flow during the rapid filling 
phase, while the second peak, or A wave, represents transmitral flow occurring 
as a result of atrial contraction. The E and A waves are two well defined peaks 
and usually display a linear upstroke and down slope that can be measured as 
acceleration and deceleration respectively, in centimeters per second. Other 
conventional measures include the peak E and A velocities, as well as the 
integrated areas within each phase, Ei and Ai. Occasionally a separate distinct 
and positive inflow wave is seen immediately after the E wave; this wave has 
been designated the L wave. A normal peak E wave velocity is in the range of 
70 to 100 cm per second, with a peak A wave velocity 40 to 70 cm per second 
resulting in an E/A ratio of 1.0 to 1.5. The normal deceleration time (DT) for 
the E wave is 160 to 220 msec. Normal values vary within echo laboratories. 
Therefore, normative data should be established for each laboratory using 
standard examination and measurement techniques so that individual subjects 
can be evaluated against control subjects.  
 
ABNORMAL TRANSMITRAL FLOW PATTERNS: 
Although the ranges for normal values are wide and Doppler parameters are 
affected by a variety of hemodynamic and physiologic factors, patients with a 
proven diastolic dysfunction have been shown to demonstrate characteristic 
abnormalities in the spectral flow profile. Three distinct clinical patterns of 
abnormal transmitral flow have been described. 
 
The first pattern consists of a prolonged IVRT (isovolumetric relaxation time) 
and deceleration time (DT) with a reduced peak E and an increased peak A 
velocity. These findings have been associated with normal early diastolic filling 
ventricular relaxation.  
 
The second transmitral flow pattern has been termed restrictive, characterized 
by a short IVRT and a reduced deceleration time, along with increased E wave 
and diminished A wave velocities. Thus the filling is shifted predominantly to 
the rapid filling phase in early diastole and is thought to be due to a high 
crossover pressure at the time of mitral valve opening in the presence of a 
relatively non-distensible left ventricle. 
 
A third pattern has been termed pseudonormal or normalized, characterized by 
normal velocities but results from counterbalancing influences of both abnormal 
relaxation and restrictive forces. The deceleration time is either normal or 
shortened.50 51,52.        
 
Figure A:  
 
 
 
E: Early diastolic filling, A: Atrial filling, 
IVRT:  Iso volumetric relaxation time, Dec.Time: Deceleration time. 
MATERIALS AND METHODS 
Study design and methods: 
Study population: 
67 patients aged between 30 and 65 years satisfied the diagnostic criteria for 
the metabolic syndrome among the patients evaluated at the medical OPD 
for non-specific symptoms and who were initially found to have either one 
or a combination of the three following,  
1. Impaired fasting glucose (more then equal to 110mg/dl) 
2. High blood pressure (more than or equal to 130/85mmHg) 
3. Obese individuals (waist circumference > 90cm in male 
     > 85 cm in female**) 
The study was conducted between January 2005 and December 2005. 
The study group included 36 females and 31 males.  
 
CONTROLS  
60 apparently healthy individuals who were age and sex matched and who 
did not have any of the criteria for metabolic syndrome were taken as 
controls for the evaluation of B mode Carotid Intima media thickness and 
diastolic dysfunction and 24 hour protein estimation. 
 
INCLUSION CRITERIA: 
1. Patients who do not have overt symptoms of diabetes mellitus (like 
polyuria, polydipsia, polyphagia, weight loss, easy fatigability etc.,) 
2. Patients who do not have overt symptoms of hypertension (headache, 
giddiness, angina, dyspnea, palpitations, leg swelling) 
3. Patients who satisfied three or more of the following five criteria,  
A. Waist circumference:   Male: 90 cms or more ** 
                      Female: 85 cms or more ** 
 
B. Fasting blood glucose:  110 mg/dl or more 
C. Blood pressure:   130/85 mmHg or more 
D. Triglycerides:    150 mg/dl or more 
E. HDL-C:        < 40 mg/dl in males 
                                  < 50 mg/dl in females 
 
 
** It is well reported in various studies that the upper limit of the Waist 
circumference has to be tailor- made for each ethnic group. 53     
(Ramachandran et al, 2003; Kim et al., 2002) 
Hence, in our study, the Modified ATP III criteria, with Waist 
circumference of more than or equal to 90cm in male, and 85 cm for female 
has been taken  2, 53, 73,74.  
 
 EXCLUSION CRITERIA: 
1. Patients who carried a diagnosis of Diabetes mellitus earlier and on anti- 
diabetic medications. 
2. Known Diabetic patients on non-pharmacological measures for blood 
sugar control. 
3. Known hypertensives on drug therapy. 
4. Known hypertensives on Life style modification protocols for blood 
pressure control. 
5. Known cases of hypercholestrolemia. 
6. Patients who have suffered a cardiovascular or cerebro-vascular event 
earlier (as defined by angina, unstable angina, MI, TIA, stroke etc.,) 
7. Patients who are known to have other end organ damage.  
8. Patients who had serious diseases like valvular heart disease, congenital 
heart disease, nephritic syndrome, nephritis, and renal failure. 
 
 
 
 
 
METHODS 
 A brief history and clinical examination was done before subjecting the 
patients for investigations. 
Patients who satisfied the diagnostic criteria for the metabolic syndrome 
were subjected to further studies that included, 
Blood urea, serum creatinine, serum electrolytes, urinalysis, and 
electrocardiography. 
Optic fundus was examined in all patients. Patients who showed any 
evidence of end-organ damage were excluded.  
Further studies on patients after applying the exclusion criteria include, 
 24-hour urine protein estimation,  
Carotid intima-media thickness by B mode Ultrasonography, 
Left ventricular diastolic dysfunction - Echocardiogram wise.  
24-hour urine protein estimation: 54  
Proteinuria was estimated from a 24-hour collection of urine sample. 
‘‘Patients are instructed to empty the bladder at the beginning of the 
collection period, discard the urine, and note the time. Then, to collect all 
urine passed (including overnight) during the subsequent 24 hours. Exactly 
24 hours after the commencement of collection, empty the bladder. Urine 
thus voided is to be collected. 
The 24-hour urine sample thus collected is submitted for quantitative 
estimation of protein. ’’ 
 
Carotid intima-media thickness: 
Carotid intima-media thickness (IMT) was measured in all the patients by B-
Mode Ultrasonography (7.5MHz probe). Three pre-defined sites (distal 
common carotid, carotid bifurcation and proximal internal carotid) on each 
side were selected for IMT and the mean derived. Two observers 
independently did the B-Mode examination at different times of the same 
day at the pre-defined sites. Inter-observer error in the evaluation of mean 
IMT was 6%.  
ECHOCARDIOGRAPHY: 
Echocardiogram was done with an ALOKA Echocardiogram machine. 
Subjects were examined in the left lateral decubitus position using standard 
parasternal short axis and apical views. All the recordings and measurements 
were done by the same observer according to the recommendations of the 
American society of echocardiography and were always performed at the 
mid-day to avoid the influence on the left- ventricular diastolic function.   
Left-ventricular diastolic dysfunction (LVDD) was evaluated using well-
standardized diagnostic criteria and all Doppler measurements were assessed 
at the end of expiration. 
From the trans-mitral recordings, the following measurements were carried 
out. Peak `E` velocity in centimeters per second (peak early trans-mitral 
filling velocity during early diastole), peak `A` velocity in centimeters per 
second (peak trans-mitral filling velocity during late diastole) and 
deceleration time in milliseconds (time elapsed between peak E velocity 
crosses the zero baseline. IVRT, (iso-volumetric relaxation time) defined as 
time elapsed between closing of aortic valve and opening of mitral valve. 
The definitions published by the Canadian consensus on diastolic 
dysfunction by echocardiography were used to classify diastolic function as 
follows,  
Normal, 
Impaired relaxation,  
Pseudo-normal and 
Restrictive pattern.  
No subject had echocardiographically detectable regional wall motion 
abnormalities and each subject had normal ejection fractions. All cardiac 
valves were examined for significant valvular disease. Two patients had 
trivial mitral regurgitation. 
Serum total cholesterol and triglycerides and HDL were analyzed enzymatic 
ally (fasting sample). Serum LDL cholesterol was calculated with 
Friedewald`s formula. 
LDL cholesterol = Total cholesterol – HDL cholesterol- TGL/5.     
 
STUDY LIMITATIONS: 
Patients selected for the study were more in the age group of 40 to 60 years 
as it is well known that increased Carotid intima- media thickness and LV 
Diastolic dysfunction can occur in aged individuals irrespective of the 
presence of the Metabolic Syndrome. This selection bias may show an 
apparently low prevalence of the Metabolic Syndrome in the elderly. 
Measurement of the Carotid intima-media thickness is not without observer 
variation. Though measures have been taken to reduce this by doing the 
same with two different observers at different times of a day, and evaluating 
the inter-observer error, minor variations are still bound to occur. 
Though all patients were subjected to urine protein estimation, the ideal 
marker of cardiovascular risk estimation is microalbuminuria rather than 
proteinuria. Proteinuria may occur in a humpty number of other conditions. 
This limitation was seriously considered and hence to rule out renal causes 
of proteinuria, all patients underwent urinalysis, blood urea, serum creatinine 
and electrolyte. However, chances of patients having very subtle renal 
dysfunction and normal lab values of such parameters are always there. 
Studies have been conducted using proteinuria instead of microalbuminuria 
for similar cardiovascular risk estimations. Based on such studies, we have 
used proteinuria instead of microalbuminuria, as the latter is not readily 
available in all centers. 70. Also, proteinuria is routinely preceded by 
microalbuminuria. 
Hence the estimation of proteinuria may be an underestimate of 
microalbuminuria and hence the cardiovascular risk. 31   
   
 
OBSERVATIONS AND RESULTS 
 
The study population consists of 67 patients with 36 females and 31 males. 
All patients studied belong to places in and around Tanjavur district, 
 Tamil Nadu. 
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AGE: 
The age of the study group was between 30 and 65. Twenty-one patients 
were between 30 and 40 years of age. Twenty-two patients were between 41 
and 50 years of age. Eighteen patients were between 51 and 60 years of age 
and two patients were above 61 years of age. 
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SOCIO-ECONOMIC GROUP:  
The study population was categorized into low, medium and high 
socioeconomic groups according to the monthly income. Patients with a 
monthly income of less than 3000 Rs per month were categorized under low, 
those between 3000 and 7000 medium, and those > 7000 as high socio-
economic class respectively. 19 patients (28.35%) of the patients fell under 
the low socio-economic group. All the remaining 48 (71.64%) fell under the 
medium group. 
 
RISK FACTORS: 
Conventional risk factors for atherosclerosis were sought in the general 
history taking of the patient and it was found that 34 patients (50.74%) had 
one or more of these factors like smoking, excess alcohol intake, sedentary 
life style habits etc. 
 
BODY MASS INDEX: 
Anthropometrical analysis of patients revealed that 22 patients (32.83%) had 
a BMI of less than 25; 36 patients (53.73%) had a BMI between 25.1 and 30; 
9 patients (13.43%) patients had a BMI of >30. Comparing the BMI with 
waist circumference the following observations were made,  
The Mean WC of patients in the normal BMI group was 87.68 
The Mean WC in the overweight group was 92.30 
The Mean WC in the obese group was 100.66. 
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METABOLIC SYNDROME: 
Applying the ATP III criteria for the diagnosis of the metabolic syndrome, 
of the 67 patients, 50 patients (74.62%) had three out of the five variables 
for the diagnosis; 13 patients (19.40%) had four out of the five variables and 
4 patients (5.97%) had all the five variables for the diagnosis of the 
metabolic syndrome. 
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Patients who showed gross ECG abnormalities like Ischemia, injury, 
infarction, left ventricular hypertrophy and conduction disturbances were 
excluded. However three patients who showed non-specific ST-T wave 
changes were included in the study. Two patients who showed trivial mitral 
regurgitation were also included, however, one patient showed a mild mitral 
regurgitation was excluded. 
 
Fifty-four patients (80%) had an increased waist circumference. 29 were 
females and the remaining 25 were males. The mean waist circumference in 
the female and male population was 92.79 and 96.2 respectively. 
 
Forty- four patients (65%) had a fasting blood sugar of more than or equal to 
110 mg/dl. 28 were females and 16 were males. The mean fasting blood 
sugar for females and males were 116mg/dl and 138mg/dl respectively. 
 
Fifty- three (79%) patients had an elevated triglyceride level of more than or 
equal to 150 mg/dl. 28 were males and 25 were females. The mean 
triglyceride levels were 189.85mg/dl and 187.44 for males and females 
respectively. 
Only thirteen patients had a HDL cholesterol level below normal. (Less than 
40mg/dl, for males and less than 50mg/dl, for females). Of these 8 were 
females with a mean HDL-C value of 40.5mg/dl and five were males with a 
mean of 30.8mg/dl. 
Fifty patients (74%) had an elevated Blood pressure, 26 were females and 24 
were males. The mean BP in the female population was 148/94 mmHg and 
in the males, 150/92 mmHg. 
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EVENTS:  
Proteinuria: 
Thirty nine patients (58.20%) had proteinuria defined by excretion of more 
than 150mg per day in a timed collection of urine. Of these, 22 were females 
and the mean level of proteinuria was 578mg per day and 17 were males 
with a mean of 558.89mg/day. 
 
Carotid Intima Media Thickness: 
Thirty-one patients (46.26%) had a carotid intima media thickness of greater 
than or equal to 0.8mm. 14 were females with a mean of 0.821mm and 17 
were males with a mean value of 0.835mm. 
 
Left ventricular Diastolic dysfunction: 
Impaired relaxation was the only diastolic dysfunction noted in subjects. No 
patient showed a restrictive or pseudonormal pattern. Of the 31 subjects who 
were found to have diastolic dysfunction, 16 were females and 15 were 
male.   
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CONTROLS: 
    Control group included 60 individuals in whom none of the criteria was 
positive for the metabolic syndrome. Such age matched and sex matched 
individuals were selected for 24 hour protein estimation, carotid intima 
media thickening and LV diastolic dysfunction study. 
It was observed that proteinuria was present in six out of the sixty 
individuals. 
Increased Carotid IMT was observed in eight out of the sixty individuals. 
Impaired relaxation was observed in six out of the sixty individuals. 
  
STATISTICAL ANALYSIS OF DATA: 
Within the group, (cases) statistical Analysis of the individual factors with 
the individual events revealed the following results, Applying the 
 Chi square test, there was a statistically significant difference between the 
means of the proteinuria group and the blood sugar values at 5% level. 
Similarly, there was a statistically significant difference between the means 
of Waist circumference and the LV diastolic dysfunction at 5% level. The 
events that occurred in rest of the factor analysis showed that even though 
there is an absolute increase in the incidence of events with the factors 
subgroups, the association was not statistically significant. 
The comparison of the study group with the control group revealed the 
following results,  
Applying the Chi square test, it was found that,   
The presence of the metabolic syndrome and the increase in the Carotid 
intima media thickness are highly associated at 5% significance level.         
(p < 0.05) and the occurrence is not mere increase in the number of cases. 
The presence of the metabolic syndrome and the occurrence of LV diastolic 
dysfunction are highly associated at 5% significant level. (p <0.05) and the 
association is not mere increase in the apparent number of cases.              
Also, the metabolic syndrome and increased protein excretion in urine are 
highly associated at 5% level of significance. (p <0.05). 
 
 CASES CONTROLS P value 
CAROTID INTIMA 
MEDIA THICKNESS 
 
39 
 
6 
<0.05 
LV DIASTOLIC 
DYSFUNCTION 
 
31 
 
8 
<0.05 
PROTEINURIA 31 6 <0.05 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
SEX: 
The metabolic syndrome is observed in more number of females than males. 
This correlates with the earlier studies, both native and foreign. According to 
Gupta et al., 2003 7.9% of males and 17.5% of females in western India 
suffer from the metabolic syndrome. A. Ramachandran et al., 2003 reports 
an increase in the metabolic syndrome in women in studies conducted in 
south India.  Jaber et al., 2004 reports 23% and 28% respectively in Arab 
Americans. Our results correlate with these studies with more females 
suffering from the metabolic syndrome. 
AGE: 
The incidence of the metabolic syndrome increases with age. Villegas et al., 
2003 reports an increasing prevalence of metabolic syndrome with 
increasing age from 20.7% in < 50 group to 24.3% in >60-year group. 
Similar results were shown by studies by Indian researchers. A. 
Ramachandran et al., reports increasing trend with age. However, in our 
study it is noticed that more number of people in the 41 to 50 years age 
group had metabolic syndrome than the >50 group. Probably this has 
occurred as a result of patient selection bias in order to include younger 
individuals as the incidence of LV diastolic dysfunction and Carotid IMT 
increases with age and this study aims to evaluate these parameters in young 
individuals with metabolic syndrome. 
SOCIO-ECONOMIC STATUS: 
A significant increase in the number of cases of metabolic syndrome in the 
medium socio-economic class was noted as compared to the low socio-
economic class. This correlates with both Indian and foreign observations 
and relates to the increasing prevalence of obesity in this group. More than 
half of the study group had a body mass index in the overweight range, i.e., 
between 25 and 30. This shows that the metabolic syndrome is more 
prevalent in the overweight group. The increased occurrence of the 
Metabolic syndrome in the obese individuals in well known. NHANES III 
study showed that the prevalence of the metabolic syndrome increased from 
up to 3% in <20 BMI group to 22.5% in the 25to 27 BMI group. Other 
studies that reported similar observations include the St. Onge, Janssen and 
Heymsfield, et al., 2004 Weiss et al., 2004 and Cook et al., 2003. 
 
RISK FACTORS: 
Conventional risk factors have a bearing in patient’s long-term morbidity 
and mortality. Common risk factors observed include history of smoking, 
excessive alcohol consumption, sedentary life style etc. almost 50% of the 
patients were observed to have at least one of these factors. Whitehall II 
study on White European civil servants found that risk factor modification 
by increasing leisure time activity was associated with a reduced incidence 
of the metabolic syndrome. Laaksonen et al., 2002 and rennie et al., 2003 
report similar results in geographically separated areas. Farrell, Cheng and 
Blair et al., 2004 report an increase in incidence of metabolic syndrome in 
smokers compared to non-smokers. 
Thus a conclusion prevails in the form of life style modifications for 
reducing the risk of metabolic syndrome.       
Factor analysis of the metabolic syndrome showed that the percentage of 
hypertriglyceridemia (79%), low HDL-C and hypertension (74%) were 
higher when compared to the Mexican study, Phase II San Antonio Heart 
study and the earlier Indian studies. This shows that there is an increased 
incidence of dyslipidemias and hypertension in this study compared to the 
other studies. This may be explained by the diet habits of the people in this 
part of the state or by some other factors to be evaluated further.  
The Clustering of risk factors occurred in both males and females in a 
comparable manner.  Earlier studies clearly show that the risk of 
cardiovascular events increased with the number of factors present within 
the metabolic syndrome group, Thus, more the clustering was, more were 
the events to occur, i.e., carotid Intima Media thickness LV diastolic 
dysfunction and proteinuria. 55  
 
 CAROTID INTIMA MEDIA THICKENING: 
The association of Carotid Intima Media thickness with the metabolic 
syndrome is found to be statistically significant in our study. The analysis 
of various other studies is as follows,  
Compared with young adults without metabolic syndrome, those with 
metabolic syndrome had greater carotid intima-media thickness on 
ultrasound, an indicator of sub- clinical atherosclerosis. Carotid intima-
media thickness increased with the number of components of the metabolic 
syndrome present.  The burden of sub-clinical atherosclerosis in young 
adults increases with an increasing burden of components of metabolic 
syndrome, and increased BP and low HDL-C are especially powerful 
predictors of increased carotid intima-media thickness.56 
Among 507 young adults (20 to 38 years old) Using ultrasound, the 
researchers measured the thickness of the inner layers of the carotid arteries. 
Carotid intima-media thickness can identify sub- clinical atherosclerosis, 
that is, hardening and thickening of the arteries before an individual feels 
any symptoms. The artery wall thickness is a predictor of cardiovascular 
risk. The study participants were also classified as having metabolic 
syndrome if they met the ATP III criteria.  This is the first study to 
demonstrate that metabolic syndrome is associated with increased sub- 
clinical atherosclerosis in otherwise healthy young adults,” Dr. Stein said. 
“Those with the thickest carotid artery walls were two to three times more 
likely to have metabolic syndrome, independently of age, sex, race and 
smoking status.” 57 
 Metabolic Syndrome and the Progression of Carotid Intima-Media 
Thickness in Elderly Women were found to be statistically significant in 
several studies. Incident metabolic syndrome is associated with accelerated 
progression of carotid IMT in elderly women, as shown in a 12-year follow-
up study in a population-based sample of 101 women (age range at baseline, 
60-70 years). 58 
Early and asymptomatic signs of atherosclerosis could be detected in 
middle-aged subjects who proved to be hyperinsulinaemic in a screening 
procedure. The prevention of clinically manifest cardiovascular diseases in 
these subjects could be of great importance.59 
The effect of the metabolic syndrome on early atherosclerosis is more 
prominent in women than in men. 60  
Studies also revealed gender differences for the subcomponents of the 
metabolic syndrome. 60 
Several studies assess the Intima-media thickness of the carotid arteries in 
subjects with hyperinsulinaemia (insulin resistance). 61 
One study evaluated the frequency of metabolic syndrome with premature 
Carotid atherosclerosis in young women with polycystic ovary disease 
(PCOD). PCOD is one another disease associated with the metabolic 
syndrome. The study was conducted in 43 young women and IMT was 
measured and concluded that factors other than hyperandrogenaemia and 
obesity might be operating as causative factors. 62 
In young adults, Metabolic Syndrome is associated with increased 
atherosclerotic burden, and therefore, increased cardiovascular risk.  
These results support the importance of screening and early intervention in 
this population.63 
 Thus, increased Carotid intima media thickness is a potential marker for 
early vascular disease in patients and pre-dates the development of cerebro-
vascular events. Interventions of various components of the metabolic 
syndrome have shown outcome benefits in several studies as discussed 
above. 
 
 
LEFT VENTRICULAR DIASTOLIC DYSFUNCTION: 
The association of the Left ventricular diastolic dysfunction with the 
metabolic syndrome is found to be statistically significant in our study. The 
analysis of various other studies is as follows,  
Several studies have reported various degrees of diastolic dysfunction in 
asymptomatic obese individuals both with and without diabetes mellitus.64 
The prevalence of left ventricular diastolic dysfunction in asymptomatic, 
normotensive patients without significant coronary artery disease is much 
higher than previously suspected. Tissue Doppler Imaging markedly 
improved the echocardiographic detection of diastolic dysfunction in 
asymptomatic patients. 65 
Obesity in young otherwise-healthy women is associated with concentric LV 
remodeling and decreased systolic and diastolic function. These early 
abnormalities in LV structure and function may have important implications 
for explaining the myocardial dysfunction that is associated with increased 
cardiovascular morbidity and mortality caused by obesity.66 
 Females with metabolic syndrome are more prone for the development of 
LV Diastolic Dysfunction 67 
The occurrence of diastolic dysfunction was independent of the systolic 
function and is the first to occur among the two.68  
Thus, diastolic dysfunction is a significant risk factor for the development of 
early cardiovascular event especially in female patients with metabolic 
syndrome. The identification of this is important as this occurs before the 
systolic dysfunction begins and interventions of various components have 
shown outcome benefits.  
 
PROTEINURIA: 
The association of the proteinuria with the metabolic syndrome is found to 
be statistically significant in our study. 
Proteinuria has emerged in the last decade as a recognized independent 
cardiovascular risk factor in addition to being a predictor of diabetic kidney 
disease.22, 23 
 It has been associated with essential hypertension, 24, 25 elevate triglycerides, 
total cholesterol and reduced HDL cholesterol, endothelial dysfunction, 26, 27, 
all features of the metabolic syndrome. 
The significance of microalbuminuria was first described in 1982 by Viberti 
et al., who showed a 24 fold increased risk of development of clinical 
proteinuria in Type 1 diabetic patients 31. The finding was later extended to 
be associated with Type 2 diabetes mellitus also. 32, 33, 34. Similar observations 
in non-diabetic individuals have also been reported in population studies 35-40. 
Thus proteinuria is an independent cardiovascular risk factor, the 
pathophysiology of which may be related to insulin resistance or 
hyperinsulinemia. It is probable that insulin resistance and proteinuria are 
both manifestations of a central mechanism yet to be identified which causes 
the clustering of metabolic and hemodynamic derangements in 
cardiovascular disease. In essential hypertension or diabetes, insulin 
resistance can be found in the absence of proteinuria but the reverse is 
uncommon. Therefore, the presence of proteinuria in these patients should 
serve as a warning signal for the metabolic syndrome.   
Two other studies postulate a different type of correlation of proteinuria with 
the metabolic syndrome. 
Proteinuria predicted cardiovascular disease mortality independently of the 
presence of metabolic syndrome in non-diabetic and diabetic Subjects. 70  
 Proteinuria predicts Type 2 diabetes, independent of the metabolic 
syndrome and other known risk markers. 71. 
  
 
CONCLUSIONS 
 
The metabolic syndrome, once thought to occur more commonly in affluent 
societies is now a common disease in people of all socio-economic strata.  
In-spite of harboring several factors of the metabolic syndrome, most 
patients are asymptomatic. 
The disease appears to have a slight female preponderance.   
Sedentary lifestyle, smoking and excess alcohol are associated with an 
increase incidence of the metabolic syndrome and studies have shown 
benefits of life style modifications. 
Body mass index, being overweight/obese and the waist circumference are 
good predictors of cardiovascular risk in patients with the metabolic 
syndrome. Control of body weight has shown to improve the outcome of 
cardiovascular events in several studies. 
The Carotid Intima media thickness, Left ventricular diastolic dysfunction 
and Proteinuria all increase with the number of factors of metabolic 
syndrome present. Several prospective studies have shown an increased 
cardiovascular mortality and morbidity in such patients. 
There is a significant increase in the incidence of Carotid Intima media 
thickness, diastolic dysfunction and Proteinuria in patients with metabolic 
syndrome compared to those who do not have metabolic syndrome. 
Since several studies have shown that these are easily detectable, early 
markers of cardiovascular and cerebro-vascular events, identification of such 
abnormalities should be sought after seriously and treatment options 
considered in reducing future hi-risk events.   
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S.NO NAME AGE SEX OP No S-E STATUS RF HEIGHT WEIGHT
Mts Kgs
1 Vanaroja 39 F 1703/05 MED NIL 1.5 65
2 Poongodi 40 F 1967/05 MED NIL 1.5 47
3 Mustafa 48 M 2029/05 MED S,A SED 1.77 83
4 Rajeshwari 42 F 2206/05 MED SED 1.45 61
5 Nachiapillai 65 M 2260/05 MED S 1.62 70
6 Tamaraiselvi 40 F 2470/05 LOW NIL 1.5 53
7 Padma 55 F 2707/05 MED SED 1.55 65
8 Selvaraj 50 M 2721/05 MED S,A 1.7 66.5
9 Sarasu 40 F 2868/05 MED NIL 1.46 62
10 JaitoonBeevi 52 F 2866/05 MED NIL 1.61 71
11 Radhakrishnan 52 M 3046/05 LOW S A 1.64 65
12 Ganesan 45 M 3067/05 LOW S A 1.55 54
13 Chandra 39 F 3206/05 LOW NIL 1.53 50
14 MohdBeevi 41 F 3280/05 MED NIL 1.4 60
15 Uthirapathi 60 M 3281/05 MED A 1.6 65
16 Muthulakshmi 39 F 3485/05 MED NIL 1.5 59
17 Kalaiselvi 45 F 3478/05 MED NIL 1.45 50
18 Karupaiyan 56 M 3481/05 MED A 1.7 61
19 Somasundaram 55 M 3536/05 MED S A 1.66 69
20 Ramamoorthy 53 M 3581/05 LOW S A 1.73 74
21 MariaJohn 43 F 3602/05 LOW NIL 1.67 66
22 Sahayamary 45 F 3641/05 LOW NIL 1.43 50
23 Nellavathy 65 F 3721/05 MED NIL 1.53 65
24 Durairaj 52 M 3892/05 LOW NIL 1.65 60
25 Mariammal 48 F 3899/05 MED NIL 1.42 67
26 Saminathan 55 M 3916/05 MED S A 1.59 61
27 Geetha 48 F 3946/05 MED SED 1.49 59
28 Gowri 32 F 3977/05 MED SED 1.75 87
29 Anandavalli 60 F 3994/05 MED NIL 1.5 59
30 SelvarajMuthu 36 M 3995/05 MED S A 1.6 82
31 Chandra 43 F 4027/05 MED NIL 1.4 64
32 Amarjothi 48 F 4039/05 MED NIL 1.56 58
33 Nallammal 60 F 4132/05 MED NIL 1.5 60
34 Leelavathy 33 F 4236/05 LOW NIL 1.56 63
35 Rajam 35 F 4247/05 MED NIL 1.52 65
36 Vasudevan 41 M 4291/05 MED A 1.72 94
37 MayaDevi 51 F 4352/05 LOW NIL 1.59 64
38 Anandaramakrishnan56 M 4355/05 LOW A 1.64 60
39 Panchavarnam 45 F 4356/05 LOW NIL 1.6 68
40 Sornam 38 F 4417/05 MED NIL 1.52 60
41 Andal 56 F 4516/05 MED NIL 1.56 63
42 Subramanian 30 M 4598/05 MED S A 1.68 88
43 Elavendan 36 M 4601/05 MED S A 1.62 75
44 Rajarajan 50 M 4701/05 MED S A 1.63 74
45 Madumadhi 36 F 4739/05 LOW NIL 1.49 59
MASTER CHART 
46 Sekar 48 M 4781/05 LOW S A 1.63 61
47 Sukanya 33 F 4795/05 MED NIL 1.62 74
48 Rajavel 42 M 4822/05 MED A 1.64 72
49 Jesima 48 F 4827/05 MED NIL 1.66 66
50 Rajasekaran 55 M 4916/05 MED S A 1.68 68
51 Sivanandam 48 M 4933/05 LOW S A 1.75 78
52 Deivendran 40 M 4934/05 MED S A 1.6 71
53 Devikala 38 F 4976/05 MED NIL 1.52 64
54 Vasanthakumari 45 F 5001/05 MED NIL 1.53 63
55 Nagarajan 48 M 5013/05 LOW S A 1.62 60
56 Sridharan 51 M 5032/05 LOW S A 1.72 69
57 Kalyani 38 F 5136/05 MED NIL 1.54 62
58 Amirtha 33 F 5207/05 MED NIL 1.6 66
59 Baskar 43 M 5417/05 MED NIL 1.58 65
60 Muralidharan 40 M 5475/05 LOW NIL 1.69 74
61 kirubha 36 M 5491/05 MED S A 1.75 94
62 sathyanathan 57 M 5791/05 LOW S A SED 1.67 64
63 Mehalai 52 F 5882/05 MED SED 1.49 63
64 venkatragavan 45 M 5889/05 MED S 1.64 72
65 kannan 38 M 5954/05 MED S A 1.67 86
66 balakrishnan 42 M 5965/05 MED S 1.72 88
67 rani 38 F 5981/05 MED NIL 1.58 63
BMI
WC(cms)
BP(mmHg
)
FBSugar(
mg/dl)
TGL(mg/dl
)
HDL-
C(mg/dl)
24 
Hr.Ur.Prot
ein
28.8 92 140/94 127 150 60 380
20.8 86 140/90 120 138 55 450
26.5 102 150/90 120 148 45 350
29 88 160/100 115 240 40 200
26.6 96 160/90 110 164 30 380
23.5 77 130/90 123 160 50 nil
27.8 96 140/90 122 126 48 325
23 98 150/90 112 180 30 475
29.1 90 140/90 100 150 50 125
27.4 92 150/100 128 249 50 740
24.25 98 124/80 128 231 48 275
22.5 93 140/86 118 122 56 406
21.6 80 128/80 134 266 45 0
30.6 97 150/100 136 120 60 1380
25.3 97 130/90 142 310 50 1220
26.2 87 130/94 132 204 60 984
23.8 83 130/86 136 166 40 289
21.1 90 136/80 128 188 52 525
25 98 180/100 116 212 86.6 1200
24.7 93 130/80 110 184 50 1200
23.74 92 130/90 111 142 55 391
24.5 83 150/100 125 300 52 138
27.7 92 160/100 102 200 55 170
22 89 138/88 115 168 65 90
33.2 108 170/90 131 145 40 1600
24.2 78 170/100 112 152 50 0
26.5 98 110/80 122 111 27 132
28.4 106 150/110 110 126 65 132
26.2 75 140/90 134 199 50 130
32 100 150/90 102 170 40 84
32.3 95 180/110 89 171 60 1270
23.8 84 130/86 116 154 50 45
26.6 98 160/80 88 150 54 325
25.9 80 120/84 116 150 44 150
28.2 88 140/90 90 160 58 220
31.8 100 154/94 80 172 40 120
25.3 88 140/100 123 140 56 85
22.3 80 134/70 121 176 30 434
26.5 90 148/94 98 156 54 50
25.9 85 134/80 116 200 58 800
25.9 93 144/90 115 148 52 376
31.2 98 142/90 98 140 50 145
28.6 90 150/86 98 178 46 145
27.9 91 148/100 130 220 50 675
26.5 88 132/90 120 194 62 890
MASTER CHART 
SYMPTOMS THE METABOLIC SYNDROME
23 85 140/90 110 172 60 75
28.2 98 150/100 80 166 65 68
26.8 94 160/90 78 196 50 78
24 90 136/90 116 140 52 325
24.1 88 140/90 94 190 40 470
25.4 98 148/94 110 182 57 375
27.7 91 120/84 122 150 54 135
27.7 88 140/90 98 173 58 0
26.9 102 150/94 130 194 48 650
22.9 90 110/70 120 180 46 50
23.3 94 140/80 122 186 34 325
26.16 90 120/80 128 210 53 75
25.7 88 140/94 92 164 58 50
26.1 91 136/90 84 150 55 115
25.96 95 140/96 90 168 54 80
30.7 109 150/94 100 194 45 54
23 80 132/76 134 211 30 480
28.3 93 162/100 94 160 40 425
26.8 100 164/90 80 226 50 78
30.93 98 150/100 86 204 40 456
30.87 101 164/98 84 202 40 255
25.3 93 144/90 118 148 52 376
Carotid 
IMT
ECHO- 
LVDD
0.8 imp.relaxation
0.82 imp.relaxation
0.76 normal
0.69 imp.relaxation
0.92 imp.relaxation
0.8 normal
0.7 normal
0.84 imp.relaxation
0.6 normal
0.82 normal
0.82 imp.relaxation
0.55 imp.relaxation
0.7 normal
0.76 imp.relaxation
0.67 imp.relaxation
0.7 normal
0.81 normal
0.82 normal
1 imp.relaxation
0.4 normal
0.8 normal
0.6 normal
0.8 imp.relaxation
0.7 normal
0.77 imp.relaxation
0.64 normal
50 imp.relaxation
0.91 imp.relaxation
0.83 imp.relaxation
0.76 normal
0.83 imp.relaxation
0.64 normal
0.78 imp.relaxation
0.84 normal
0.62 normal
0.8 normal
0.68 imp.relaxation
0.81 imp.relaxation
0.66 normal
0.76 normal
0.78 imp.relaxation
0.86 imp.relaxation
0.6 normal
0.8 normal
0.72 normal
EVENTS
0.62 normal
0.8 imp.relaxation
0.8 imp.relaxation
0.75 normal
0.8 normal
0.74 normal
0.62 normal
0.56 normal
0.81 imp.relaxation
0.64 normal
0.8 imp.relaxation
0.66 normal
0.62 normal
0.65 normal
0.7 normal
0.8 imp.relaxation
0.86 imp.relaxation
0.72 normal
0.81 imp.relaxation
0.86 imp.relaxation
0.8 imp.relaxation
0.83 imp.relaxation



